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Gordon D Murray, professor,1 Peter Sandercock, professor,3 Isabella Butcher, research fellow,1
F Gerald R Fowkes, professor,1 on behalf of the AAA Trialists
ABSTRACT
Objective To determine the effects of low dose aspirin on
cognitive function in middle aged to elderly men and
women at moderately increased cardiovascular risk.
DesignRandomiseddouble blindplacebo controlled trial.
Setting Central Scotland.
Participants 3350 men and women aged over 50
participating in the aspirin for asymptomatic
atherosclerosis trial.
Intervention Low dose aspirin (100 mg daily) or placebo
for five years.
Main outcome measures Tests of memory, executive
function, non-verbal reasoning, mental flexibility, and
information processing five years after randomisation,
with scores used to create a summary cognitive score
(general factor).
ResultsAt baseline,mean vocabulary scores (an indicator
of previous cognitive ability) were similar in the aspirin
(30.9, SD 4.7) and placebo (31.1, SD 4.7) groups. In the
primary intention to treat analysis, there was no
significant difference at follow-up between the groups in
the proportion achieving over the median general factor
cognitivescore (32.7%and34.8%respectively, odds ratio
0.91, 95% confidence interval 0.79 to 1.05, P=0.20) or in
mean scores on the individual cognitive tests. There were
also no significant differences in change in cognitive
ability over the five years in a subset of 504 who
underwent detailed cognitive testing at baseline.
Conclusion Low dose aspirin does not affect cognitive
function in middle aged to elderly people at increased
cardiovascular risk.
Trial registration ISRCTN 66587262.
INTRODUCTION
Cognitive function declines with age, and such decline
is of increasing public health concern because of the
burden it imposes on individuals, carers, and the wider
society.1 2 Reduced levels of cognitive performance in
older age have been associated with the presence of
cardiovascular disease,3 4 possibly mediated through
multiple small cerebral infarcts frommicroatheromaor
thromboses in the brain. Antithrombotic medication
such as aspirin might therefore have a role in the
preservation of cognitive function, particularly in
individuals at increased risk of atherosclerotic vascular
disease.Conversely, if aspirinpromotesmicrohaemor-
rhages in the brain, this might exacerbate cognitive
decline. Observational studies have reported either no
associationbetween regular use of aspirin or other non-
steroidal anti-inflammatory drugs and cognitive
decline in older age56 or a modest trend towards
protection of cognitive function.7-10 Data from rando-
misedcontrolled trials, however, are sparse.The results
of a recent large clinical trial indicated that long term
low dose aspirin had no effect on memory in healthy
women aged over 64, with inconclusive findings for
executive function.11 Conversely, a much smaller trial
inmen aged over 55without dementiawhowere at risk
of cardiovascular disease suggested a beneficial effect
of low dose aspirin on verbal fluency and mental
flexibility.12
We determined the effects of long term low dose
aspirin on a wide range of cognitive functions that are
known to decline with age in a relatively young
population (aged 50 and over) of men and women at
moderately high vascular risk. We included two
cognitive assessments, one at baseline and one after
five years, in an ongoing randomised controlled trial of
daily aspirin (100 mg enteric coated) in people aged
over 50, in which the primary end points were
cardiovascular events and death (the aspirin for
asymptomatic atherosclerosis (AAA) trial). At rando-
misation, all participants in this trialwere atmoderately
increased cardiovascular risk because of a low ankle
brachial index, a reduced ratio of systolic blood
pressure in the ankle to that in the arm, which is a
good predictor of increased mortality and cardio-
vascular events.13
METHODS
Participants
This double blind, placebo controlled randomised
clinical trial took place in central Scotland (Lanark-
shire, Edinburgh, and Glasgow) in 1998-2006. All
participants gave written informed consent. Volun-
teers aged 50-75 were recruited by direct mailing of
people registered with participating general practices
(83% of practices contacted agreed to participate).
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People were ineligible for screening if they had had a
previousmyocardial infarctionor strokeor if theywere
taking aspirin or warfarin. The study was advertised in
the local press and by posters in general practices.
At a screening clinic researchers recorded right and
left brachial, posterior tibial, and dorsalis pedis systolic
pressures with a standard sphygmomanometer and a
Doppler probe. The ankle brachial index was calcu-
lated as the ratio of the lowest pressure in either ankle to
the higher of themeasurements in the left or right arm.
Exclusion criteria instituted at the screening clinic
included an ankle brachial index >0.95 in both legs;
current use of aspirin, other antiplatelet, or anti-
coagulant; severe indigestion; history of myocardial
infarction, stroke, angina, or peripheral arterial dis-
ease; chronic liver or kidney disease; chemotherapy;
contraindications to treatment with aspirin; and an
abnormally high or low packed cell volume.
Participants were randomised to either daily aspirin
(100 mg enteric coated) or identical placebo (both
preparations provided by Bayer HealthCare). Con-
secutive subject study numbers were assigned to
aspirin or placebo with permuted blocks of size eight,
which varied randomly. A specialist member of staff
who was not otherwise involved in the study produced
the randomisation list. Staff at a single dedicated
pharmacy labelled bottles containing aspirin or pla-
cebo with the appropriate subject numbers. Recruits
entering the trial were then allocated the next available
study number and provided with the appropriately
labelled bottle containing one year’s supply of tablets.
Randomisation lists in sealed envelopeswere available
only to the pharmacy, to an independent member of
staff who was responsible for unblinding individual
participants in the case of clinical necessity, and to an
independent statistician responsible for providing
annual reports to the data monitoring committee.
Staff working on the trial, the investigators, and
participants remained blinded to treatment allocation.
Participants were contacted annually by telephone
and newsletter, in between which they were encour-
aged to report admission to hospital or cessation of
study medication. If they stopped study medication
other than for a medical reason, they were actively
encouraged to start again. If they started taking aspirin
or anotherantiplateletdrug, their studymedicationwas
discontinued. Participants recorded their compliance
in a diary. A specially trained research nurse assessed
self reported compliance annually, afterwhich supplies
of study tablets were renewed by post.
Cognitive function testing
Participants underwent neuropsychological tests three
months after they had started the trial medication
(baseline cognitive testing) and at five years. At
baseline, they completed a combined version of the
Junior and Senior Form A synonyms of the Mill Hill
vocabulary scale.14 They were presented with a word
and asked to identify the closest synonym from six
given alternatives. TheMillHill scale, in commonwith
other vocabulary tests, is primarily an indicator of
previous (“best ever” or premorbid) cognitive ability,
which changes little with age.15 16 It was used to
compare the baseline characteristics of the trial
population and to enable assessment of the impact of
any difference in previous cognitive ability on loss to
follow-up and on change in cognitive performance
over time. The test has been shown previously to
correlate highly with other tests of previous cognitive
ability that are used in a similar manner.17
At about five years, participants underwent a battery
of tests in apredeterminedorder to assess abroad range
of cognitive functions (230 participants were tested
after four years, 259 after six years, two after seven
years, and the remainder at five years). The mini-
mental state examination18 was included as a general
mental assessment and is often used as a “screen” for
dementia. Executive function was assessed with the
verbal fluency test,19 which requires participants to
generate as many words as possible with a specified
initial letter (C, F, and L). As a measure of non-verbal
reasoning, participants worked through all five sets (A
to E, containing 12 items each) of Raven’s progressive
matrices14 andwere scored according to the number of
items they completed correctly within 20 minutes.
Immediate and delayedmemorywas assessedwith the
total score on the first five trials (I through V,
constituting the same list of 15 words) of the auditory
verbal learning test.19 The trail making test20 measured
Ineligible: ABI >0.95 (n=24 066)
Ineligible (n=1564):
  Failed eligibility criteria (n=631)
  Declined to participate (n=933)
Assessed for eligibility (n=28 980)
Entered pre-randomisation stage (n=4914)
Randomly allocated (n=3350)
Allocated to placebo (n=1675)Allocated to aspirin (n=1675)
Cognitive change
subset who underwent
full/partial* cognitive
test battery at
baseline (n=254)
Lost to cognitive
testing at follow-up†
(n=536, 32%)
Lost to cognitive
testing at follow-up
(n=63, 24.8%)
Cognitive test battery
at average 5.1 years in
trial (n=1139, 967 full,
172 partial*)
Cognitive change
subset who underwent
full/partial* cognitive
test battery at
baseline (n=250)
Lost to cognitive
testing at follow-up†
(n=489, 29.2%)
Lost to cognitive
testing at follow-up
(n=42, 16.8%)
Cognitive test battery
at average 5 years in
trial (n=1186, 1017
full, 169 partial*)
Cognitive test battery
at average 5 years in
trial (n=191)
Cognitive test battery
at average 5 years in
trial (n=208)
Study population and follow-up. *At least one cognitive test in battery of tests completed.
†Breakdownof reasons for loss to follow-upby treatmentallocationnot given topreserveblinding
withinmain trial until cardiovascular endpoint reached.See text forbreakdownof reasons for total
trial population (including 160 deaths)
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mental flexibility, and the time taken to completepartB
was used in the subsequent analysis. In the digit symbol
test,21 used as a measure of speed of information
processing, we recorded the number of symbols
matched correctly to their corresponding numbers in
90 seconds. The hospital anxiety and depression scale
(A and D)22 was also used for the assessment of mood
states, as these can affect performance on the tests. At
follow-up the national adult reading test measured
premorbid cognitive ability.23
In addition, we undertook a highly sensitive assess-
ment of cognitive change over time in a “cognitive
change subset” of recruits who underwent the same
detailed battery of tests as above at baseline. We
recruited 504 participants at baseline for this purpose
from consecutive participants who agreed to complete
the Mill Hill vocabulary scale during the period May
2000 to March 2001. Baseline and follow-up cognitive
test scores were available on 399 participants in this
subset.
Data analysis
We used each participant’s score on the Carstairs
deprivation index, based on the postal code classifica-
tion from the 1991 census,24 25 to assign a deprivation
category ranging from I (most affluent) to VII (most
deprived).24 Further statistical analysis was carried out
with SAS/STAT software, version 9.1, of the SAS
System for Windows (SAS Institute, Cary, NC).
Our primary analysis was on an intention to treat
basis, using both individual test scores and the
proportion of participants achieving over an aggregate
cognitive score. For the latter, those not achieving the
aggregate scorewould include those failing to complete
cognitive testing at follow-up, thereby reducing bias
from death or unwillingness to complete the tests
(likely to be associated with greater cognitive decline).
We estimated that 3300 participants would give 93%
power at 5% significance to detect a difference of 47%
versus 53% attaining the threshold. For the cognitive
change subset, we estimated that two groups of 200
would provide 80% power to detect a treatment effect
size of 0.28 standarddeviations at 5% significance (90%
power for 0.33 SD). Allowing for loss to follow up, we
aimed to recruit at least 480 participants into the subset
at baseline.
Principal components analysis was carried out to
determine a summary cognitive score (the general
factor) for the cognitive function variables (auditory
verbal learning, Raven’s matrix, digit symbol, verbal
fluency, and trail making) with scree slope analysis to
determine the number of factors. Where one or two of
the test results were missing for an individual, we
performed multiple imputation, accounting for age,
reading score, sex, and deprivation score. This analysis
resulted in a single component (the general factor,
reflecting general cognitive ability26), which explained
58% of the total variance (standardised scoring
coefficients: auditory verbal learning 0.23, Raven’s
matrices 0.28, digit symbol 0.29, verbal fluency 0.22,
trail making −0.28). This component was extracted as
the first unrotated principal component. We subse-
quently used the median general factor score for all
participants with such a score available as the cut-off
point for the aggregate cognitive score used to assign
participants into two groups in the primary analysis.
We determined differences in mean cognitive test
scores between the aspirin and placebo groups at
follow-up using Student’s t tests. For the cognitive
change subset, results are presented as estimates (with
95%confidence intervals) of thedifferencebetween the
two treatments at follow-up for the factor score and for
each individual test of cognition. The difference
between the treatments for each variablewas estimated
after adjustment for baseline values in the first model
andbaselinevalues, age, sex, anklebrachial index, total
plasma cholesterol concentration, smoking status, and
deprivation category in the second model.
Interim analyses of cognitive data were not con-
ducted during the course of the study. The primary end
points, including the aggregate cognitive score, and
statistical comparisons were prespecified. All P values
were two sided and were not adjusted for multiple
testing.
RESULTS
Primary analyses
Of the 28 980 participants screened, 24 066 were
excluded because they had an ankle brachial index
>0.95 in both legs. Before randomisation, 631 did not
meet other eligibility criteria and 933 declined to take
Table 1 | Characteristics of participants* at randomisation. Figures aremeans (SD) unless stated
otherwise
Characteristic Aspirin group (n=1675) Placebo group (n=1675)
Age (years) 62 (7) 62 (7)
No (%) of men 481 (29) 473 (28)
No (%) by Carstairs deprivation category†:
I/II 287 (17) 300 (18)
III/IV/V 927 (55) 884 (53)
VI/VII 458 (27) 489 (29)
Ankle brachial index 0.86 (0.09) 0.86 (0.09)
Systolic blood pressure (mm Hg) 149 (22) 147 (22)
Diastolic blood pressure (mm Hg) 84 (11) 84 (11)
Total plasma cholesterol (mmol/l) 6.2 (1.1) 6.2 (1.1)
No (%) of smokers:
Current 548 (33) 539 (32)
Previous‡ 540 (32) 561 (34)
Never 587 (35) 575 (34)
Mill Hill vocabulary scale score 30.9 (4.7) 31.1 (4.7)
No (%) by recruitment centre:
Edinburgh 388 (23) 364 (22)
Glasgow 478 (29) 497 (30)
Lanarkshire 809 (48) 814 (48)
*Data available for all participants except for deprivation score (n=1673 in both groups), diastolic blood
pressure (n=1674 in aspirin group and 1671 in placebo group), plasma cholesterol (n=1663 and 1666), Mill Hill
vocabulary scale score (n=1361 and 1372).
†I (most affluent) to VII (most deprived).
‡Smokers who had stopped smoking for at least 6 months before randomisation.
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part (figure). The 3350 remaining were randomly
assigned to aspirin or placebo. Table 1 shows the
characteristics of the two groups at randomisation. In
total, 2733 (81.6%) participants (1361 in the aspirin
group and 1372 in the placebo group) agreed to
complete the Mill Hill vocabulary scale (MHVS).
Mean scores on this test were similar between the two
groups (30.9 (SD 4.7) and 31.1 (SD 4.7), respectively).
A total of 1025 participants were lost to cognitive
follow-up: 317 withdrew (n=157) or died (n=160)
before testing, 668 refused the cognitive assessments
either in a research clinic or in their own homes, 27
could not be contacted, and 13 were not tested for
practical reasons (including serious illness and living
abroad). Table 2 shows the characteristics at rando-
misation of the participants who completed at least one
cognitive test at follow-up compared with those not
cognitively tested. Those not testedwere slightly older,
more likely to be men, and more socially deprived,
with a poorer vascular risk factor profile. Differences
between the tested and untested groups in previous
cognitive abilitywere small (vocabulary score 31.1 (SD
4.7) v 30.6 (SD 4.6), P=0.03).
Of the 2325 participants cognitively tested, 1984
completed the full test battery. Fourteen omitted the
adult reading test only and264 omitted only one or two
of the tests used to generate the general cognitive factor
score (in which case we calculated their general factor
score using imputation). Thus a general factor score
was calculated for 2262 participants (1109 in aspirin
group and 1153 in placebo group). For the purposes of
the primary end point analysis, all 1088 participants
without a general factor score at follow-up were
included in the group who did not achieve the
aggregate score.
Overall, 32.7% (n=548) of participants in the aspirin
group and 34.8% (n=583) in the placebo group
achieved over the median general factor score (odds
ratio 0.91, 95% confidence interval 0.79 to 1.05,
P=0.20). There was little change in the odds ratio
after adjustment for age, sex, ankle brachial index,
deprivation category, smoking status, and total plasma
cholesterol (0.93, 0.80 to 1.08, P=0.35). These results
did not alter greatly when we repeated analyses
excluding participants without a general factor score,
with proportions of 49.4% and 50.6%, respectively,
achieving over themedian score (unadjusted 0.96, 0.81
to 1.13, P=0.59; adjusted 0.98, 0.82 to 1.17, P=0.83).
Table 3 shows themean test scores at follow-up in the
two groups. There was no significant difference
between the two groups for any of the individual tests
or for the general factor. The proportion of participants
scoring below 24 on themini-mental state examination
was similar (2.4% (27) v 2.5% (29), P=0.91). There was
also no significant difference in mean scores on the
hospital anxiety scale (5.2 (SD 3.6) v 5.4 (SD 3.6),
P=0.12) or the hospital depression scale (2.9 (SD 2.5) v
3.0 (SD 2.7), P=0.82).
Analysis of cognitive change subset
Table 4 shows that therewereno significant differences
in the change in cognitive ability over the five years for
any of the individual tests or for the general factor
between the treatment groups. Scores for tests of speed
of processing information and mental flexibility in the
cognitive change subset declined over the five years,
though the change in mental flexibility scores was not
significant (mean digit symbol 45.0 at baseline, 42.4 at
follow-up, P<0.001: mean trail making 94.2 seconds at
baseline, 97.4 seconds at follow-up, P=0.2). There was
no significant difference over time in verbal fluency or
non-verbal reasoning and scores on the memory test
improved (mean auditory verbal learning 63.8 at
baseline, 68.5 at follow-up, P<0.001). Changes
observed over time are probably underestimates of
the true age related declines26 because the effects of age
can be ameliorated by familiarity with the test.
To examine whether compliancemight have affected
our results, we performed an on treatment analysis for
participantswho reported that theyhad taken their study
medication for at least two thirds of the year before
follow-up. This analysis was planned before unblinding
the treatment allocations, but after the data had been
collected. Some1708participantswere confirmedas still
taking treatment. Of the 1642 remaining, 160 had died,
269 had had a cardiovascular event, 203 had started
taking aspirin for a reason other than a cardiovascular
event, 317 had reported known side effects of aspirin or
had startedmedication contraindicatedwith aspirin, 250
had developed other symptoms or illnesses unrelated to
aspirin, and 404 simply no longer wanted to take the
studymedication (statusof 27wasunknownand12were
Table 2 | Characteristics of participants* at randomisation by cognitive test status at follow-up.
Figures aremeans (SD) unless stated otherwise
Characteristic
Cognitively tested
(n=2325)
Not cognitively tested
(n=1025) P value†
Age (years) 62 (7) 63 (7) 0.001
No (%) of men 627 (27) 327 (32) 0.004
No (%) by Carstairs deprivation category‡:
I/II 444 (19) 143 (14)
<0.001III/IV/V 1269 (55) 542 (53)
VI/VII 610 (26) 337 (33)
Ankle brachial index 0.86 (0.09 0.85 (0.10 0.003
Systolic blood pressure (mm Hg) 147 (21) 149 (22) 0.02
Diastolic blood pressure (mm Hg) 84 (11) 83 (11) 0.26
Total plasma cholesterol (mmol/l) 6.2 (1.1) 6.2 (1.1) 0.99
No (%) of smokers:
Current 671 (29) 416 (41)
<0.001Previous§ 779 (33) 322 (31)
Never 875 (38) 287 (28)
Mill Hill vocabulary scale score 31.1 (4.7) 30.6 (4.6) 0.03
*Data available for all participants except for deprivation category (n=2323 in tested group, 1022 in untested
group), diastolic blood pressure (n=2322 and 1023), plasma cholesterol (n=2314 and 1015), Mill Hill
vocabulary scale score (n=2202 and 531).
†P values from χ2 test for categorical variables and t test for continuous variables except ankle brachial index
(Mann-Whitney test).
‡I (most affluent) to VII (most deprived).
§Smokers who had stopped smoking for at least 6 months before randomisation.
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still taking studymedicationbut for less than two thirdsof
preceding year).
Of theparticipants still taking treatment at follow-up,
850 were in the aspirin group and 858 were in the
placebo group.Therewere no significant differences in
baseline characteristics between these two groups (data
not shown). In each group42.8% (364) and 45.8% (393)
achieved over the median general factor score (0.89,
0.73 to 1.07, P=0.22). Of the 2325 participants
cognitively tested at follow-up, 1505 (64.7%) were
still taking treatment (743 and 762, respectively). The
characteristics at randomisation of these two groups
were also similar (data not shown). Mean (SD)
cognitive scores at follow-up for the aspirin and
placebo treatment groups, respectively, were general
factor 0.0 (1.0) in both groups; Raven’s matrix 34.3
(9.6) and34.8 (9.2); auditoryverbal 63.5 (16.7) and63.3
(16.7); digit symbol 40.6 (11.9) and 40.8 (11.7); verbal
fluency 37.8 (13.1) and 37.8 (12.7); trail making 4.6
(0.4) and 4.6 (0.4); and mini-mental state <24 2.7%
(n=20) and 1.9% (n=14, P=0.26).
DISCUSSION
In this large double blind, placebo controlled rando-
mised clinical trialwe foundno significant difference in
measures of cognitive function between people rando-
mised to 100 mg aspirin daily compared with placebo
over a five year period. Our initial hypothesis was
based on observed associations between cardio-
vascular disease and cognitive decline3 4 and the
positive effects of aspirin on the incidence of cardio-
vascular events in both primary and secondary
prevention trials,27 28 although it has been argued that
aspirin might alter the presentation of cardiovascular
disease rather than affecting underlying disease
processes.29 30 There is also evidence that non-steroidal
anti-inflammatory drugs might reduce neurotoxic
inflammatory responses in the brain or reduce the
cellular response to excessive stimulation by excito-
toxins, or both.10 Our results, however, do not support
a beneficial effect of aspirin on cognitive performance
in middle aged to elderly people at increased cardio-
vascular risk.While aspirin couldbe expected tohave a
beneficial role in reducing large vessel cerebral
occlusive disease and small vessel disease caused by
“microatheroma,” it might not influence (and might
even exacerbate) other forms of small vessel disease,
such as arteriosclerosis with diffuse white matter
damage from ischaemia or “leaky vessels,”31 with or
without microhaemorrhages.
Veracity of findings
We studied men and women at increased risk of
developing symptomatic cardiovascular disease in
whom the effect of aspirin might be expected to be
accentuated (correlations of between 0.03 and 0.15
between ankle brachial index and cognitive function
have been reported, depending on the cognitive tests
performed32). The trial had sufficient power to detect
small differences in cognitive function between the
groups, and we used various tests to assess a range of
cognitive abilities. As virtually all neuropsychological
tests are highly intercorrelated, we used a summary
cognitive score that represents their shared variance to
determine the effect of aspirin on global cognitive
capacity. As each test measures a specific aspect of
cognition that might differ in its response to treatment
we also analysed the test scores individually. In our
robust statistical analyses we used a prespecified
primary outcome measure that took into account
possible associations between performance on the
cognitive tests and ability or willingness to complete
the cognitive test at follow-up.
The effect of aspirin on cognitive performancemight
be more evident in younger people,7 and cerebral
damage caused by micro-thromboses and other
Table 3 | Performance on cognitive function tests at follow-up*
Test of cognition
Aspirin group (n=1139) Placebo group (n=1186)
P valueNo of participants Mean (SD) score; 95% CI No of participants Mean (SD) score; 95% CI
General cognitive factor score (summary
cognitive score)†
1109 0.00 (1.01); −0.06 to 0.06 1153 −0.01 (0.99); −0.06 to 0.05 0.83
Raven’s progressive matrices (5 sets of 12
item tests; maximum possible score 60)
1110 34.3 (9.5); 33.8 to 34.9 1153 34.4 (9.3); 33.9 to 35.0 0.83
Auditory verbal learning, trials I-V (sumof five
trials with same list; maximum possible 75
words)
1118 63.0 (16.7); 62.1 to 64.0 1159 63.0 (16.9); 62.0 to 64.0 0.93
Digit symbol (total No of symbols matched
correctly in 90 second test; maximum
possible score 93)
1126 40.0 (11.7); 39.3 to 40.7 1170 40.0 (11.7); 39.4 to 40.7 0.92
Verbal fluency (total No of words generated
in three 1 minute tests)
1117 37.6 (12.8); 36.9 to 38.4 1156 37.1 (12.7); 36.3 to 37.8 0.27
Trail making (seconds to completion)‡ 1122 4.6 (0.4); 4.6 to 4.6 1167 4.6 (0.4); 4.6 to 4.6 0.90
Mini-mental state examination (total score,
maximum possible 30)
1131 28.6 (1.7); 28.5 to 28.7 1178 28.5 (1.8); 28.4 to 28.6 0.20
*In all tests except trail making, higher scores indicate better function. Imputed test scores were used for individuals with ≤2 scores missing for Raven’s progressive matrices (162 scores
imputed), auditory verbal learning (95), digit symbol (10), verbal fluency (45), and trail making (37).
†Calculated from factor analysis with unrotated principal component analysis with current cognitive function measures excluding mini-mental state.
‡Natural log of time in seconds to complete trail making test (untransformed means 102 seconds for aspirin group and 101 seconds for placebo group).
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neurodegenerative processes might start to become
established in middle age. This hypothesis, however,
was not supported by our post hoc analyses (data not
shown) in which separation of the total trial population
into those aged 50-64 and those aged 65 or older had
little impact on the overall results.
Inability to study the effects of aspirin on younger
peoplewasoneof the limitationsof a recent clinical trial
by Kang et al of the effects of aspirin on memory.11
Anotherwas its restriction towomen.Again in post hoc
analysis, we found no effect of aspirin on verbal
memory inwomen (mean auditory verbal score 65.2 in
aspirin group v 65.4 in placebo group, P=0.84) or men
(57.2 v 56.5, P=0.62). Crucially, we also studied the
effect of aspirin on cognitive functions other than
memory, including executive function, non-verbal
reasoning, mental flexibility, and information proces-
sing. Our findings that aspirin had no effect on these
additional measures of cognitive ability contrast with
those from the only other clinical trial of low dose
aspirin to investigate similar outcomes.12 The latterwas
a relatively small trial (n=405), however, involving the
cognitive testingof a subgroupofmen still participating
in a clinical trial several years after randomisation.
Furthermore, there was no baseline measure of
cognitive function, and some participants received
warfarin as well as aspirin.
Limitations and strengths
A high proportion of participants (30%) failed to
complete the cognitive tests at follow-up. This level of
non-testing was largely inevitable in a long term
intervention study in “healthy” volunteers (the num-
bers included deaths and trial withdrawals as well as
those who refused to take tests) andwas consistent with
previous studies of a similar design. In the study by
Kang et al, only 71% of women initially randomised to
aspirin or placebo and selected to take part in the
cognitive study agreed to undergo both baseline and
follow-upcognitive testing four years later.11Relatively
high levels of non-testing could have biased our
findings, especially as it has been shown previously
that people with poor cognitive function are more
likely to withdraw from studies.33 In our study,
however, there was only a small difference in Mill
Hill vocabulary scores at baseline between those who
did and did not undergo cognitive testing at follow-up.
Thepotential effect of cognitivedeclineover theperiod
of the study on test completion was further addressed
by use of the aggregate cognitive score in our primary
analysis.
Despite concerted efforts to maintain participants’
compliancewith studymedication, this fell throughout
the duration of the trial and could have affected our
results. For the purposes of the “on treatment” analysis,
we used a rigorous definition of on treatment and
included only participants who reported that they had
taken their study medication for at least two thirds of
the year before follow-up. This was consistent with
definitions used in previous primary prevention
trials.34 All participants randomised to aspirin, how-
ever, took their studymedication for at least someof the
trial period before stopping at various stages through-
out the trial, such that the total proportion of person
years on aspirin was actually much higher than that
suggestedby thenumberof participants included in the
on treatment analysis. The issue of compliance was
further addressed by the on treatment analysis itself,
which failed to show any difference in the aggregate or
meancognitive scoresbetween those takingaspirinand
those taking placebo, or indeed any shift in the overall
results that might have indicated an effect of aspirin.
We cannot exclude the possibility that higher doses
or longer duration of aspirin treatment, or both, would
have led to different results. The participants, although
at increased risk of developing symptomatic cardio-
vascular disease, were free from clinical cardiovascular
disease at baseline and otherwise generally healthy.
Our follow-up period, although comparing favourably
with previous trials on age related cognitive decline,
might have been short for such a relatively young and
healthycohort.Wecouldnot assess theactualdegreeof
cognitive decline in the population because perfor-
mance on a given cognitive test (especially memory
tests) is known to improve as the test is repeated, even
after several years, simply because participants are
familiar with the testing procedure (learning effect).35-37
A population with advanced vascular disease,
Table 4 | Change inmean (SD) cognitive test scores in cognitive change subset participating at baseline and follow-up*
Test of cognition†
Aspirin Placebo Difference (aspirin-placebo) (95% CI), P value
Follow-up
score
Change from
baseline‡
Follow-up
score
Change from
baseline‡
Adjusted for
baseline value
Fully
adjusted§
General factor score 0.39 (0.89) 0.26 (0.45) 0.37 (0.89) 0.27 (0.47) −0.01 (−0.09 to 0.08), 0.89 0.01 (−0.07 to 0.09), 0.77
Raven’s progressive matrices 37.8 (8.9) −0.1 (5.9) 37.5 (8.9) −0.6 (5.4) 0.5 (−0.6 to 1.6), 0.34 0.7 (−0.3 to 1.8), 0.17
Auditory verbal learning 68.0 (15.2) 3.9 (11.5) 68.3 (16.1) 5.2 (11.2) −1.1 (−3.3 to 1.1), 0.32 −0.7 (−2.9 to 1.4), 0.51
Digit symbol 42.7 (10.8) −2.6 (6.2) 42.3 (11.6) −2.5 (6.3) 0.0 (-1.2 to 1.2), 0.96 0.3 (−0.9 to 1.5), 0.62
Verbal fluency 41.4 (11.5) 0.6 (7.5) 41.3 (11.3) 0.8 (7.8) −0.1 (−1.6 to 1.3), 0.88 −0.2 (−1.6 to 1.3), 0.84
Trail making 4.50 (0.37) 0.02 (0.28) 4.51 (0.38) 0.02 (0.31) 0.00 (−0.06 to 0.06), 1.00 −0.01 (−0.07 to 0.04), 0.61
*No of participants for each analysis is 399 (including 25 with some imputation at follow-up), 191 in aspirin group and 208 in placebo group.
†See table 3 for details of tests.
‡Score at follow-up minus score at baseline.
§Additional adjustment for age, sex, and baseline values for ankle brachial index, total plasma cholesterol, smoking status, and Carstairs deprivation category.
Interaction terms for test specific baseline covariate and treatment group were examined and none was significant.
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dementia, or established mild cognitive impairment
might have had a different response, asmight any other
population with more marked middle to late life
cognitive decline. Longer follow-up into older age
might also be necessary to showany “delayed” effect of
aspirin from the time of altered cerebral pathology to
development of observable changes in cognitive
decrements.
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